This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Campbell, I. W Search for Related Content Social Bookmarking                         What's this?

The STORM report: implications for care

The appropriate use of sibutramine in Primary care is discussed by Dr Ian Campbell, Chair of the National Obesity Forum

Campbell Park House Medical Centre, 61 Burton Rd, Carlton, Nottingham, NG4 3DQ, UK, iwc9{at}yahoo.com

Sibutramine is a newly available satiety-inducing agent which also increases energy expenditure. Its efficacy was evaluated with a two-year controlled study called STORM (Sibutramine Trial of Obesity Reduction and Maintenance). 605 obese subjects (BMI 30—45 kg/m²) were recruited, and 499 completed an initial six months of exercise, diet and sibutramine (10 mg/day) therapy. 93% achieved >5% weight loss. After a further 18 months of this treatment most subjects maintained 80% of their body weight loss whereas subjects receiving placebo tablets regained over 75% of their weight loss. The STORM trial suggests that sibutramine promotes weight loss and may assist weight control in obese subjects unable to maintain adequate dietary regimens, whereas efficacy of the pancreatic lipase inhibitor orlistat is dependent on dietary compliance.

Key Words: sibutramine • serotonin noradrenaline re-uptake inhibitor • obesity • STORM study.

References

• Health Survey for England: Cardiovascular Disease 1998, HMSO, London, 1999.
• Pi-Sunyer F. Medical hazards of obesity. Ann Intern Med 1993;119:655-60.[Abstract/Free Full Text]
• Mathias S., Williamson C., Colwell H. et al. Assessing health-related quality-of-life and health state preferences in persons with obesity: a validation study. Qual Life Res 1997;6:311-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Goldstein D. Beneficial health effects of modest weight loss. Int J Obes 1992;16:397-415.[Web of Science][Medline] [Order article via Infotrieve]
• Barsh G., Farooqi I., O'Rahilly S. Genetics of body-weight regulation. Nature 2000;404:644-51.[Web of Science][Medline] [Order article via Infotrieve]
• Wadden T., Sternberg J., Letizia K. et al. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes 1989;13(suppl 2):39-46.[Web of Science][Medline] [Order article via Infotrieve]
• Sjöström L. Natural history of massive obesity. Obes Res 1995;3:317.
• Abenhaim L., Moride Y., Brenot F. et al. for the International Primary Pulmonary Hypertension Study Group. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335: 609-16.[Abstract/Free Full Text]
• James WPT, Astrup A., Finer N. et al. for the STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000;356:2119-25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hansen D., Toubro S., Stock M. et al. Thermogenic effects of sibutramine in humans. Am J Clin Nutr 1998;68:1180-6.[Abstract]
• Smith I., Goulder M. for the Sibutramine Clinical Study 1047 Team. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001;50:505-12.[Web of Science][Medline] [Order article via Infotrieve]
• Finer N., Bloom S., Frost G. et al. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diab Obes Metab 2000;2:105-12.[CrossRef]
• Department of Health. National Service Framework for Coronary Heart Disease: Modern Standards and Service Models. HMSO London, 2000.
• Tuomilehto J., Lindström J., Eriksson J. et al. for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.[Abstract/Free Full Text]
• Hansen D., Astrup A., Toubro S. et al. for the STORM study group. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Int J Obes 2001;25:496-501.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Scottish Intercollegiate Guidelines Network. Obesity in Scotland: Integrating Prevention with Weight Management. Edinburgh, Scotland. SIGN, 1996.
• Royal College of Physicians. Clinical Management of Overweight and Obese Patients with Particular Reference to the Use of Drugs. RCP, London, 1998.
• Astrup A., Rössner S. Lessons from obesity management programmes: Greater initial weight loss improves long-term maintenance. Obesity Reviews 2000;1:17-19.[CrossRef][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 1, No. 2, 118-121 (2001)
DOI: 10.1177/14746514010010021001


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Campbell, I. W Search for Related Content Social Bookmarking                         What's this?